|Referral date||01 November 2011|
Scoped as part of Batch 20
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|Project manager:||Lori Farrar|
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for vorinostat in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
For further information on our processes and methods, please see our CHTE processes and methods manual